- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00552058
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
10. juli 2018 opdateret af: UCB Pharma
Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
439
Fase
- Fase 3
Udvidet adgang
Ledig uden for det kliniske forsøg.
Se udvidet adgangsregistrering.
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Adelaide, Australien
-
Bankstown, Australien
-
Clayton, Australien
-
Fitzroy, Australien
-
Fremantle, Australien
-
Garran, Australien
-
-
New South Wales
-
Concord, New South Wales, Australien
-
-
Victoria
-
Box Hill, Victoria, Australien
-
Footscray, Victoria, Australien
-
Parkville, Victoria, Australien
-
-
-
-
-
Bonheiden, Belgien
-
Brussels, Belgien
-
Gent, Belgien
-
Leuven, Belgien
-
Liege, Belgien
-
Roeselare, Belgien
-
-
-
-
-
Curitiba, Brasilien
-
Goiania, Brasilien
-
Porto Alegre, Brasilien
-
Rio de Janeiro, Brasilien
-
Santo-Andre, Brasilien
-
Santos, Brasilien
-
Sao Paulo, Brasilien
-
-
MG
-
Belo-Horizonte, MG, Brasilien
-
-
-
-
-
Calgary, Canada
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Kelowna, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
Kingston, Ontario, Canada
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
-
-
-
Santiago, Chile
-
Vina del Mar, Chile
-
-
-
-
-
Kazan, Den Russiske Føderation
-
Moscow, Den Russiske Føderation
-
St. Petersburg, Den Russiske Føderation
-
-
-
-
-
Tallin, Estland
-
Tartu, Estland
-
-
-
-
-
Mikkeli, Finland
-
-
-
-
Alabama
-
Pell City, Alabama, Forenede Stater
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater
-
Lakewood, Colorado, Forenede Stater
-
Littleton, Colorado, Forenede Stater
-
-
Florida
-
Hollywood, Florida, Forenede Stater
-
Jacksonville, Florida, Forenede Stater
-
New Port Richey, Florida, Forenede Stater
-
Winter Park, Florida, Forenede Stater
-
-
Illinois
-
Chicago, Illinois, Forenede Stater
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater
-
-
Louisiana
-
Metairie, Louisiana, Forenede Stater
-
Monroe, Louisiana, Forenede Stater
-
-
Maryland
-
Annapolis, Maryland, Forenede Stater
-
Towson, Maryland, Forenede Stater
-
-
Michigan
-
Chesterfield, Michigan, Forenede Stater
-
West Bloomfield, Michigan, Forenede Stater
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater
-
-
North Carolina
-
Raleigh, North Carolina, Forenede Stater
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater
-
Cleveland, Ohio, Forenede Stater
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Forenede Stater
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater
-
-
Washington
-
Seattle, Washington, Forenede Stater
-
-
-
-
-
Beer Sheva, Israel
-
Haifa, Israel
-
Holon, Israel
-
Jerusalem, Israel
-
Kfar Saba, Israel
-
Petha Tikva, Israel
-
Rehovot, Israel
-
Tel Aviv, Israel
-
Zerifin, Israel
-
-
-
-
-
Bologna, Italien
-
Padova, Italien
-
Roma, Italien
-
-
-
-
-
Riga, Letland
-
Valmiera, Letland
-
-
-
-
-
Auckland, New Zealand
-
Christchurch, New Zealand
-
Hamilton, New Zealand
-
-
Auckland
-
Milford, Auckland, New Zealand
-
-
Wellington
-
Newton, Wellington, New Zealand
-
-
-
-
-
Czestochowa, Polen
-
Lodz, Polen
-
Warszawa, Polen
-
Wroclaw, Polen
-
-
-
-
-
Bucharest, Rumænien
-
Cluj Napoca, Rumænien
-
Constanta, Rumænien
-
-
-
-
-
Hradec Kralove, Tjekkiet
-
Hradek Kralove, Tjekkiet
-
Praha 7, Tjekkiet
-
Usti Nad Orlici, Tjekkiet
-
Zlin, Tjekkiet
-
-
-
-
-
Berlin, Tyskland
-
Frankfurt, Tyskland
-
Freiburg, Tyskland
-
Homburg, Tyskland
-
Jena, Tyskland
-
Kiel, Tyskland
-
Munchen, Tyskland
-
Ulm, Tyskland
-
Wilhelmshaven, Tyskland
-
-
-
-
-
Dniepropetrovsk, Ukraine
-
Donetsk, Ukraine
-
Kiev, Ukraine
-
Kyiv, Ukraine
-
Lviv, Ukraine
-
Simferopol, Ukraine
-
-
-
-
-
Budapest, Ungarn
-
Gyor, Ungarn
-
Nagykanizsa, Ungarn
-
Szeged, Ungarn
-
Szombathely, Ungarn
-
-
-
-
-
Wien, Østrig
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- male/female
- 18 - 75 years inclusive
- diagnosis of Crohn's disease confirmed
- moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
- no previous treatment with anti-tumor necrosis factor (anti-TNF) medications
Exclusion Criteria:
- previous participation in a certolizumab pegol study
- general exclusion criteria as common for studies in this indication
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
|
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Andre navne:
|
|
Placebo komparator: Placebo
Placebo, saline solution for sc injection
|
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Subjects in Clinical Remission at Week 6
Tidsramme: Week 6
|
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Subjects Achieving a Clinical Response at Week 6
Tidsramme: Week 0, Week 6
|
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
Tidsramme: Week 6
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 6
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
Tidsramme: Week 0 to Week 6
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 6
|
|
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
Tidsramme: Week 0 to Week 6
|
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item).
The first three items are scored for the previous day.
Lower scores indicated better well being.
|
Week 0 to Week 6
|
|
Percentage of Subjects in Clinical Remission at Week 2
Tidsramme: Week 2
|
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 2
|
|
Percentage of Subjects in Clinical Remission at Week 4
Tidsramme: Week 4
|
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 4
|
|
Percentage of Subjects Achieving a Clinical Response at Week 2
Tidsramme: Week 0, Week 2
|
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 2
|
|
Percentage of Subjects Achieving a Clinical Response at Week 4
Tidsramme: Week 0, Week 4
|
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
Tidsramme: Week 0 to Week 2
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 2
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
Tidsramme: Week 0, Week 4
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
Tidsramme: Week 2
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 2
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
Tidsramme: Week 4
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 4
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Tidsramme: Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Tidsramme: Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Tidsramme: Week 0, Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Tidsramme: Week 0, Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.
- Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.
- Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930. Epub 2014 Aug 22.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. marts 2008
Primær færdiggørelse (Faktiske)
1. oktober 2009
Studieafslutning (Faktiske)
1. november 2009
Datoer for studieregistrering
Først indsendt
18. oktober 2007
Først indsendt, der opfyldte QC-kriterier
31. oktober 2007
Først opslået (Skøn)
1. november 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
9. august 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. juli 2018
Sidst verificeret
1. oktober 2011
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- C87085
- 2007-001913-41 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .